TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01847651

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Assessement (Cogstate)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood and urine sampling
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blood and urine sampling
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional assessment
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional assessment
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI brain and spectroscopy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI brain and spectroscopy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI leg cross section
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI leg cross section
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (working memory and attention tasks)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional MRI (working memory and attention tasks)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study: NCT04174495

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA and CT-scan
Description: DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
Study: NCT03781479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT04361279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-02
Description: Injection，100mg/10ml
Study: NCT01566513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Connector
Description: The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Mentor
Description: A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Case Manager
Description: A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
Study: NCT02179281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic MiniMed™ 640G system
Description: The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed™ 640G system
Description: The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
Study: NCT04361279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Injection，100mg/10ml
Study: NCT03049644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Diagnosis and Therapy
Description: Identification of directional preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
Study: NCT02094391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
Study: NCT04616898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Bliss
Description: The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Bliss
Description: The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Bliss
Description: The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
Study: NCT00718185

Intervention type: PROCEDURE
Intervention: Obtain blood specimens
Description: Obtain blood samples at multiple timepoints.
Study: NCT02164110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvichol
Description: * Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: * Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose
Study: NCT01896973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vortx Rx - Histotripsy BPH Device
Description: Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
Study: NCT02248571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered as combined therapy with Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered as combined therapy with Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: administered as combined therapy with Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: administered as combined therapy with Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: administered as combined therapy with Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: administered as combined therapy with Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: administered as combined therapy with Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: administered as combined therapy with Everolimus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionaires
Description: Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionaires
Description: Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
Study: NCT03324841

Intervention type: DIAGNOSTIC_TEST
Intervention: Caris MI Profiling
Description: Customized comprehensive biomarker testing
Study: NCT00924274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rapeseed oil
Description: rapeseed oil in amounts between 14 and 27 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sunflower oil
Description: sunflower oil
Study: NCT00468247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator
Description: Navigator circulatory mgt system
Study: NCT01311180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensoril®
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Study: NCT03542071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-protein based diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Study: NCT01002534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: Nasal instillation of Vardenafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal instillation of placebo matching in appearance with the Vardenafil instillation
Study: NCT03264508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: 30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water immersion
Description: 30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature \>0.2°C.
Study: NCT00313807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid
Description: 7% amino acid infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline Infusion
Study: NCT04673526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic intersphincteric resection
Description: Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
Study: NCT04176367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicergoline from China
Description: This is the test arm of China local manufactured Nicergoline
Study: NCT04673526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic abdomino-perineal procedures
Description: Abdominoperineal resection + colostomy in left iliac fossa or perineum
Study: NCT03003416

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
Study: NCT05844800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nuss repair of Pectus Excavatum
Description: The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
Study: NCT01930799

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic Screening and Education Regimen
Description: Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
Study: NCT00365716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
Description: 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40
Description: 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
Description: 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (mcg) (Aluminum Adjuvant)225
Description: placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (mcg) (Aluminum Adjuvant) 450
Description: placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
Study: NCT01655823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sham treatment acting as control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham treatment acting as control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: Comparison of different dosages of Tetrodotoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: Comparison of different dosages of Tetrodotoxin
Study: NCT00468247

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care
Description: Conventional haemodynamic care
Study: NCT01655823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: Comparison of different dosages of Tetrodotoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: Comparison of different dosages of Tetrodotoxin
Study: NCT02674737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine, tramadol and flurbiprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol and flurbiprofen
Study: NCT02244723

Intervention type: OTHER
Intervention: Lung ultrasound examination
Description: Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
Study: NCT01893190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Based upon Investigator Judgement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Microparticles
Description: Based upon Investigator Judgement
Study: NCT02773238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Tc-99m MAA or Tc-99m DTPA

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo functional avoidance radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Albumin Aggregated
Description: Undergo Tc-99m MAA SPECT/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Undergo Tc-99m sulfur colloid
Study: NCT03181165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate Therapeutic Nutrition
Description: The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
Study: NCT04355156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: * All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)
Study: NCT03153787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
Study: NCT02025088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction.
Study: NCT00124462

Intervention type: DEVICE
Group type: OTHER
Intervention: Realigning knee brace and custom orthodic
Description: A valgus brace, customized functional orthotic for neutral foot position and motion control footwear

Intervention type: DEVICE
Group type: OTHER
Intervention: Realigning knee brace and custom orthodic
Description: A valgus brace, customized functional orthotic for neutral foot position and motion control footwear

Intervention type: DEVICE
Group type: OTHER
Intervention: Non realigning knee brace and flat orthodic
Description: A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole

Intervention type: DEVICE
Group type: OTHER
Intervention: Non realigning knee brace and flat orthodic
Description: A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole